We are live on ! Find out more
IMMU

Immunomedics Inc
IMMU

Delisted

IMMU was delisted on the 22nd of October, 2020.

192 hedge funds and large institutions have $3.48B invested in Immunomedics Inc in 2018 Q2 according to their latest regulatory filings, with 44 funds opening new positions, 79 increasing their positions, 51 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

132% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 19

90% more capital invested

Capital invested by funds: $1.83B → $3.48B (+$1.65B)

55% more repeat investments, than reductions

Existing positions increased: 79 | Existing positions reduced: 51

14% more funds holding

Funds holding: 168192 (+24)

13% more funds holding in top 10

Funds holding in top 10: 89 (+1)

36% less call options, than puts

Call options by funds: $118M | Put options by funds: $184M

Holders
192
Holders Change
+24
Holders Change %
+14.29%
% of All Funds
4.4%
Holding in Top 10
9
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+12.5%
% of All Funds
0.21%
New
44
Increased
79
Reduced
51
Closed
19
Calls
$118M
Puts
$184M
Net Calls
-$65.4M
Net Calls Change
-$72.2M
Name Holding Trade Value Shares
Change
Change in
Stake
GTC
26
Ghost Tree Capital
New York
$29.6M -$12.1M -600,000 -32%
FCMI
27
Foresite Capital Management IV
California
$29.2M +$3.18M +158,271 +15%
Susquehanna International Group
28
Susquehanna International Group
Pennsylvania
$27.7M +$8.23M +409,428 +54%
FLAM
29
First Light Asset Management
Minnesota
$27.4M +$2.77M +137,578 +13%
DM
30
Deerfield Management
New York
$26.6M +$3.91M +194,352 +21%
Ameriprise
31
Ameriprise
Minnesota
$25M -$3.45M -171,554 -14%
Goldman Sachs
32
Goldman Sachs
New York
$22.5M +$7.12M +354,499 +60%
Norges Bank
33
Norges Bank
Norway
$20.8M +$109K +5,436 +0.6%
Point72 Asset Management
34
Point72 Asset Management
Connecticut
$19.6M +$7.65M +380,516 +85%
Charles Schwab
35
Charles Schwab
California
$18.6M +$4.76M +236,774 +43%
Capital World Investors
36
Capital World Investors
California
$18.6M
Franklin Resources
37
Franklin Resources
California
$18.4M +$1.73K +86 +0%
CS
38
Candriam SCA
Luxembourg
$17.5M +$2.83M +141,000 +24%
Bank of New York Mellon
39
Bank of New York Mellon
New York
$16.7M +$2.11M +104,742 +17%
EAM
40
Eventide Asset Management
Massachusetts
$16.5M +$14M +699,000 New
SAM
41
Sectoral Asset Management
Quebec, Canada
$16.5M +$14M +695,735 New
UBS AM
42
UBS AM
Illinois
$16.2M +$12.2M +606,701 +776%
PAM
43
Panagora Asset Management
Massachusetts
$15.4M +$989K +49,205 +8%
Morgan Stanley
44
Morgan Stanley
New York
$13.5M +$852K +42,381 +8%
Massachusetts Financial Services
45
Massachusetts Financial Services
Massachusetts
$13.1M +$155K +7,694 +1%
MMH
46
Menora Mivtachim Holdings
Israel
$12.1M +$10.2M +509,900 New
RSCM
47
Rock Springs Capital Management
Maryland
$11.8M +$1M +50,000 +11%
RPAM
48
Rhenman & Partners Asset Management
Sweden
$10.8M +$804K +40,000 +10%
Invesco
49
Invesco
Georgia
$10.5M +$2.44M +121,370 +37%
FCM
50
Farallon Capital Management
California
$9.47M +$8.04M +400,000 New

IMMU Hedge Fund Activity: Q2 2018 in Review

192 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Immunomedics Inc (IMMU) for Q2 2018, worth a combined $3.48B — up 90% from $1.83B a quarter earlier.

Buyers outnumbered sellers: 44 funds opened new IMMU positions and 19 closed out — a net gain of 25 holders — while 79 added to existing stakes and 51 trimmed.

The largest buyer was Vanguard Group, adding an estimated $113M. The largest seller was NEA Management Company, exiting entirely with an estimated $40.5M sold.

  • 192 institutional investors held Immunomedics Inc (IMMU) as of Q2 2018, up from 168 in Q1 2018.
  • Funds reported $3.48B of Immunomedics Inc stock for Q2 2018, up 90% quarter-over-quarter.
  • 44 funds opened new Immunomedics Inc positions in Q2 2018 and 19 closed out, a net change of +25 holders.
  • The largest Immunomedics Inc buyer in Q2 2018 was Vanguard Group, an estimated $113M added.
  • The largest Immunomedics Inc seller in Q2 2018 was NEA Management Company, an estimated $40.5M sold.

Based on aggregated 13F filings for Q2 2018.